Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: tas0612 | 0.80 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 141 | 0.85 |
| pathways Reactome | 7 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 12822
Sealed predictions
- RPS6KA3 in dopamine neurons, braak+0.44 (p 0.240) → +0.27 (p 0.474)receipt 12829
Swarm cases
receipt 12829: RPS6KA3 in dopamine neurons, braak
- power
- full sample +0.38 (p 0.120, n 18), 95% CI -0.11 to +0.72. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.58 (p 0.011, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.57 (p 0.014, n 18). not the mix.
- skeptic
- leave-one-out range +0.29 to +0.55, sign flips 0; without severely affected donors +0.38 (p 0.120, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RPS6KA3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts